Motley Fool Asset Management LLC Boosts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Motley Fool Asset Management LLC raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 10,457 shares of the medical equipment provider’s stock after purchasing an additional 657 shares during the period. Motley Fool Asset Management LLC’s holdings in Intuitive Surgical were worth $3,528,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. OFI Invest Asset Management purchased a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $25,000. Baystate Wealth Management LLC raised its holdings in shares of Intuitive Surgical by 150.0% in the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the period. MCF Advisors LLC raised its holdings in shares of Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 40 shares during the period. Headinvest LLC purchased a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $28,000. Finally, Stone House Investment Management LLC raised its holdings in shares of Intuitive Surgical by 100.0% in the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 4,318 shares of the company’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the sale, the executive vice president now directly owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 4,318 shares of the stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the sale, the executive vice president now directly owns 189 shares of the company’s stock, valued at $69,958.35. The disclosure for this sale can be found here. Insiders sold a total of 255,736 shares of company stock valued at $98,639,667 in the last three months. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded down $1.89 on Thursday, hitting $373.12. 1,262,491 shares of the company’s stock were exchanged, compared to its average volume of 1,667,548. The firm’s 50-day moving average is $386.26 and its 200 day moving average is $345.39. The company has a market capitalization of $132.35 billion, a PE ratio of 67.35, a P/E/G ratio of 4.83 and a beta of 1.36. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 EPS. On average, analysts anticipate that Intuitive Surgical, Inc. will post 4.84 EPS for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of several research analyst reports. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Mizuho upped their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Wells Fargo & Company upped their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Piper Sandler upped their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Finally, Jefferies Financial Group upped their price target on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.